What Amperos does
Amperos runs an AI-native denial management and revenue recovery platform for healthcare providers, handling claims from submission through payment. The company combines AI agents with human revenue-cycle-management specialists to manage denials, resubmissions, and complex recovery cases, and says it serves over 3,000 clinical locations across all 50 states, recovering nearly $700 million a year across more than 500,000 claims. Amperos cites industry data that 12% of claims were denied in 2024, representing $262 billion in lost provider revenue. The company was founded in 2025 by CEO Michal Miernowski and is based in New York.
Amperos is a healthcare tool on Falcoscan. AI-native platform that automates healthcare insurance claim denial recovery. Falcoscan rates Amperos with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Amperos is founded in 2025, currently at Series_a stage. Pricing: Paid.